Krzysztof Chylinski
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Journal: Cancer discovery
Published: March 12, 2024
A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo.
A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo.
Journal: Nature communications
Published: October 03, 2022
CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two loci.
Journal: Nature communications
Published: April 01, 2019
Bridge helix arginines play a critical role in Cas9 sensitivity to mismatches.
Journal: Nature chemical biology
Published: September 19, 2018
RNA sequencing uncovers antisense RNAs and novel small RNAs in Streptococcus pyogenes.
Journal: RNA biology
Published: November 19, 2015
Classification and evolution of type II CRISPR-Cas systems.
Journal: Nucleic acids research
Published: April 15, 2014
Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems.
Journal: Nucleic acids research
Published: November 26, 2013
The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
Journal: RNA biology
Published: April 09, 2013
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
Journal: Science (New York, N.Y.)
Published: June 30, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026